Beyond Genomics and AstraZeneca to apply Systems Biology to Toxicology Study
"By partnering with AstraZeneca, a global leader in pharmaceutical research and development, in the important area of toxicology, we can demonstrate that BG's Systems Biology approach delivers critical knowledge that can be applied to reduce development costs and advance drugs with improved safety profiles," Muz Mansuri, Executive Chairman of Beyond Genomics explained.
BG's proprietary Systems Biology platforms generate BioSystem Markers(TM), unique molecular "signatures" indicative of various biological states such as health, disease, therapeutic response, or, in the case of predictive toxicology, early indicators of a toxic response. BioSystem Markers(TM) are discovered by using relevant human or animal samples and are comprised of one or more biomolecular class (e.g., transcript, protein, and metabolite) that, when evaluated together, are uniquely characteristic of a biological state.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.